Concerto HealthAI Real World Data Used to Demonstrate Positive Impact of Broadened vs. Traditional Eligibility Criteria

Research presented as part of press program abstract at 2019 ASCO Annual Meeting; Various inclusion/exclusion criteria explored to understand impact on cohort selection, sample size, line of therapy and patient outcomes; Research authors “urge all clinical trial sponsors to adopt these criteria.”

June 3, 2019

Read more

Concerto HealthAI to Showcase 1st End-to-End RWD and AI Technology Framework for Life Sciences and RWE Solutions at ASCO 2019

Ecosystem of products that configure with any data or technology enable speed, scale and efficiencies in variety of research, from clinical drug development to outcomes and market access studies; Live demonstrations on how these technology applications drive faster research speeds, faster time-to-insights and faster time-to-market for innovative therapies

June 1, 2019

Read more

4 Research Abstracts Use Concerto HealthAI RWD to Study Cancer Patients with Autoimmune Disease Frequently Excluded from Clinical Trials

The research is being presented at 2019 ASCO Annual Meeting; Application of Concerto HealthAI’s unique tech-enabled structured and abstracted datasets derived from ASCO’s CancerLinQ Discovery®

May 30, 2019

Read more

Concerto HealthAI to Present AI Model for Predicting Survival of Lung Cancer Patients, with Wide-Ranging Uses for Clinical Development

Research on AI model to be presented at ASCO 2019 Annual Meeting; Useful for assessing patient risk and treatment options, evaluating cost and quality of care or determining trial eligibility

May 28, 2019

Read more

Concerto HealthAI to Present AI Model for Identifying Metastatic Status of Cancer Patients with High Accuracy Using Structured EHR Data at ISPOR 2019

Compared to business rules alone, the model correctly identified 32% more metastatic breast cancer cases; Substantial time and resource savings for life science research

May 14, 2019

Read more

Astellas and Concerto HealthAI to Launch Real-World Evidence Initiative on Acute Myeloid Leukemia Focused on Improving Patient Treatment and Outcomes

Harnessing Real-World Data and advanced Outcomes Science to understand AML treatment patterns, disease progression, opportunities

April 10, 2019

Read more

Concerto HealthAI Enters Precision Oncology Collaboration with Pfizer

Integration of Concerto HealthAI’s Real-World Data and Advanced AI Capabilities Will Accelerate Patient Insights and Outcomes Studies

April 9, 2019

Read more

Bristol-Myers Squibb and Concerto HealthAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations

Multi-year strategic agreement that will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate next-generation research models

March 28, 2019

Read more

3 Senior Data Scientists Join Concerto HealthAI to Lead Innovation in AI and Deep Learning Applications for Life Sciences

44 Patents Filed or Granted Among Three New Hires with Deep Expertise in AI Research, Validation and Application Development

March 4, 2019

Read more

Concerto HealthAI to Present at J.P. Morgan’s 37th Annual Healthcare Conference

New CEO to Focus on Enterprise-Level Transformation of Healthcare Industry Through Real World Evidence Solutions and AI Insights Platform

January, 7, 2019

Read more

CancerLinQ LLC, Concerto HealthAI, and Tempus are Expanding Collaboration with U.S. Food and Drug Administration on Checkpoint Inhibitors

Technology Companies Concerto HealthAI and Tempus Join to Conduct Data Analysis

August 22, 2018

Read more
Read more